NYSEAM:PLXBiotechs
A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance
Why Protalix BioTherapeutics is Back on Investors’ Radar
Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone.
See our latest analysis for Protalix BioTherapeutics.
The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...